acadia pharmaceuticals inc acad said friday its stock will be halted from trading friday as a us food and drug administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with alzheimers disease psychosis the fdas psychopharmacologic drugs advisory committee will review acadias nuplazid at a meeting scheduled for 845 am eastern about six million people living in the us have alzheimers disease according to the alzheimers association and about 30 of those suffer from psychosis acadia shares have fallen 16 in the year to date while the sp 500 spx has fallen 23